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Accepted 11 April 2013AbstractThe primary treatment options for cervical cancer are surgery and radiation for more than a century. However, over the last 40 years
chemotherapy has been building up its reputation in the management of cervical cancer in various forms such as chemoradiation, neoadjuvant
chemotherapy, and palliative chemotherapy for advanced or recurrent disease. Among these, in this review, chemotherapy for advanced or
recurrent cervical cancer will be discussed.
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According to the GLOBOCAN report in 2008, cervical
cancer was the third most common type of cancer in women
worldwide, following breast and colorectal cancer. In 2008
alone, 530,232 women were diagnosed with cervical cancer. It
was also the fourth most common cause of female mortality,
responsible for 275,008 deaths [1]. Although the incidence of
cervical cancer has declined in developed countries, in Japan
approximately 12,000 women were estimated to be affected by
invasive cervical cancer, with 3,500 deaths reported in 2008.
Cervical cancer has been treated with surgery or radio-
therapy, or both, for a long time; but, over the last 40 years, a
number of cases have been treated with a third method,
namely, chemotherapy. However, because a large number of
patients with recurrent disease develop tumors in previously
irradiated areas, malignant tumor cells are surrounded by
fibrotic and avascular tissue. As a result, the concentration of
chemotherapeutic agent in the tumor is not enough to achieve
a high clinical outcome. Therefore, chemotherapy has been* Corresponding author. Department of Obstetrics and Gynecology, Kurume
University School of Medicine, Asahi-Machi 67, Kurume-Shi 830-0011,
Japan.
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ordinary treatment option, as a palliative measure.Chemotherapy for recurrent or advanced cervical
cancerFor the treatment of recurrent and advanced cervical can-
cers, chemotherapy has proven to be palliative. The activity of
single agents against recurrent or advanced squamous cell
carcinoma of the cervix reported before 1976 is listed in
Table 1 [2]. When used individually, these agents have shown
only relatively low efficacy. However, in the late 1970s,
several multidrug regimens were tested, as part of a Phase II
study, hoping for signs of increased antitumor effectiveness
[3e8]. However, each of these trials enrolled only a small
number of patients, and no regimens were tested as random-
ized trials on a large scale. In the 1980s many newly developed
antitumor agents emerged and were tested in Phase II studies
(Table 2). Among these studies of single-use chemotherapeutic
agents, cisplatin showed a higher response rate (RR) than
other agents in many Phase II trials [9].
Based on the results obtained in these studies, cisplatin
became the key drug for advanced or recurrent cervical cancer.
The next logical step was to find the appropriate dose and
administration schedule of cisplatin, and therefore, the Gy-
necologic Oncology Group (GOG) conducted a randomizedcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Single-agent chemotherapy for cervical cancer before 1976.
Drug Objective
response (%)
Cyclophosphamide 29/188 15
Chlorambucil 11/44 25
Melphalan 4/20 20
5-Fluorouracil 29/140 21
Methotrexate 12/77 16
Vincristine 10/44 23
Bleomycin 17/172 10
Adriamycin 5/28 18
Mitomycin C 4/18 22
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schedule of cisplatin: 50 mg/m2 every 21 days, 100 mg/m2
every 21 days, and 20 mg/m2 for 5 consecutive days repeated
every 21 days [19]. Four hundred ninety-seven patients
participated in this study and the RRs were 20.7%, 31.4%, and
25.0%, for regimens 1, 2, and 3, respectively; the complete
remission rates were 10.0%, 12.7%, and 8.6% for regimens 1,
2, and 3, respectively. The median duration of response ranged
from 3.9 to 4.8 months, the median progression-free interval
from 3.7 to 4.6 months, and the median survival time from 6.1
to 7.1 months. The difference in RRs for regimens 1 and 2 is
statistically significant ( p ¼ 0.015), but less than the magni-
tude originally considered clinically significant. The differ-
ences in complete remission rates, response duration,
progression-free interval, and survival times are not statisti-
cally significant. The regimen consisting of a single dose of
100 mg/m2 cisplatin produced a statistically significant higher
RR than the 50 mg/m2 regimen, while producing no appre-
ciable differences in complete remission rate, response dura-
tion, progression-free interval, or survival. In addition, the
higher dose regimen was associated with greater myelosup-
pression and nephrotoxicity. Based on the antitumor effect,
toxicity, and feasibility, a dose of 50 mg/m2 every 21 days
became the standard administration method for cisplatin.
Thereafter, various drugs were tested in combination with
cisplatin in a Phase III setting, in order to obtain better survival
rates (Table 3). Because ifosfamide achieved a high RR next to
cisplatin, ifosfamide plus cisplatin (IP) was compared with
cisplatin only [20]. The results showed that the IP regimen hadTable 2
Chemotherapeutic agents introduced to Phase II trial.
Drug Objective
response (%)
Cisplatin [9] 190/815 23
Carboplatin [10] 27/175 15
Ifosfamide [9] 35/157 14e40
Paclitaxel [11] 9/52 17
Irinotecan [12] 13/55 24
Topotecan [13] 8/43 19
Gemcitabine [14] 2/25 8
Vinorelbine [15] 6/42 15
Docetaxel [16] 2/23 9
Doxorubicin (Doxil) [17] 3/26 11
Mitolactol [18] 16/55 29a significantly higher RR and longer progression-free survival
(PFS); however, the overall survival (OS) rate was almost the
same. Moreover, toxicity of the IP regimen was more severe
than cisplatin alone, and therefore, IP was not widely
accepted. The addition of bleomycin to IP did not yield any
additional therapeutic gain [21]. Paclitaxel showed only a 17%
RR when used alone [10]; however, when used in combination
with cisplatin, it achieved a RR of 46%, despite the fact that
91% of the treated patients were previously given radiation
[22]. In a randomized Phase III study of cisplatin with and
without paclitaxel, cisplatin with paclitaxel (TP) showed
significantly better RR and PFS. Regarding OS, PC tended to
show better results than cisplatin alone, and the increase in
toxicity of TP was mild [23]. Thereafter, PC seemed to be the
standard regimen in advanced and recurrent cervical cancer.
Treatment method consisting of a combination of topotecan
and cisplatin (TopoP) showed significantly better results than
cisplatin alone in terms of RR, PFS, and OS [24]; however,
TopoP showed high hematological toxicity, and between the
two treatment groups, there was a bias in the time from initial
diagnosis to study entry, which influenced the OS rate. At the
same time, the GOG reported two Phase II studies on cisplatin
plus vinorelbine, and cisplatin plus gemcitabine [25,26].
Because both combinations were promising, the GOG con-
ducted a four-arm Phase III study comparing TP (reference
arm) with the three other combinations. In this study, there
were no significant differences in RR, median PFS, or OS
among the four regimens [27]. As a result, TP was considered
as the standard regimen for recurrent and advanced cervical
cancer.
Patients with recurrent or advanced cervical cancer, how-
ever, often have problems in the urinary tract, which can
induce renal dysfunction. For such patients, administration of
cisplatin was difficult owing to its renal toxic effects. Carbo-
platin, despite being a derivative of cisplatin, was gaining
attention because of its low renal toxic effect and there is no
need of hydration. Thus, carboplatin was tested in a Phase II
study, but it achieved a RR of only 15%, which was lower than
expected [11]. A Phase II study suggested that carboplatin plus
paclitaxel (TC) could be superior to TP in terms of RR and OS
[28]. Thus, the Japan Clinical Oncology Group conducted a
randomized Phase III study to evaluate the clinical benefit of
TC compared with TP for patients with advanced or recurrent
disease. The objective response was 60% for TP and 62% for
TC. The median OS and PFS were 18.3 and 6.9 months for TP
and 17.5 and 6.2 months for TC. Thus, TC proved comparable
with TP in terms of its antitumor activity. The TC was also less
toxic than TP in inducing febrile neutropenia, creatinine
elevation, and nausea/vomiting. This Phase III study therefore
drew the conclusion that TC could be recommended as the
new standard treatment for advanced and recurrent cervical
cancer [29].Second-line chemotherapyThigpen et al studied 34 patients with advanced or recurrent
disease who were treated with cisplatin (intravenously
Table 3
Phase III studies for advanced and recurrent cervical cancer.
No. of
pts
Histology Regimen RR (%) Median PFS (Mo) Median
OS (Mo)
Omura GA et al. [20] 454 SCC Cisplatin 50 mg/m2 vs 18 3.2 6.1
Cisplatin 50 mg/m2 þ ifosfamide 5 g/m2 31* 4.6* 7.1
Bloss JD et al. [21] 303 SCC Cisplatin 50 mg/m2 þ ifosfamide 5 g/m2 vs 32 4.6 8.5
Cisplatin 50 mg/m2 þ ifosfamide 5 g/m2 þ bleomycin 30 U 31 5.1 8.4
Moore DH, et al. [23] 280 SCC Cisplatin 50 mg/m2 vs 19 2.8 8.8
Cisplatin 50 mg/m2 þ paclitaxel 135 mg/m2 (24 hr) 36* 4.8* 9.7
Long HG, et al. [24] 293 Cisplatin 50 mg/m2 vs 13 2.9 6.5
Cisplatin 50 mg/m2 þ topotecan 0.75 mg/m2/day, d1-3 27* 4.6* 9.4*
Monk BJ, et al. [27] 513 SCC, AC Cisplatin 50mg/m2 þ paclitaxel 135 mg/m2 (24 hr) 29 Hazard ratio to TP
Cisplatin 50 mg/m2 þ vinorelbine30 mg/m2/day, d1,8 26 1.36 1.15
Cisplatin 50 mg/m2 þ gemcitabine1000 mg/m2/day, d1, 8 22 1.39 1.32
Cisplatin 50 mg/m2 þ topotecan 0.75 mg/m2/day, d1-3 23 1.27 1.26
Kitagawa R, et al. [29] 253 SCC, AC Cisplatin 50 mg/m2 þ paclitaxel135 mg/m2 (24 hr) 123 6.9 18.3
Carboplatin AUC5 þ paclitaxel 175 mg/m2 (3 hr) 121 6.2 17.5
*p < 0,05 RR: overall response rate, PFS: progression-free interval, OS: overall survival, TP:Cisplatin50 mg/m2 þ paclitaxel135 mg/m2(24 hr).
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GOG [30]. The overall frequency of response was 52.94% (18/
34). Of the 22 patients who received no prior chemotherapy,
three complete and eight partial responses were observed (RR
50%), whereas only two partial responses were observed among
the 12 patients receiving prior chemotherapy (RR 17%). The
observed RR was significantly higher, albeit marginally, among
those with no prior chemotherapy ( p ¼ 0.059). Thus, prior
chemotherapy was thought to diminish the effect of second-line
chemotherapy. Because chemoradiation with cisplatin has
become popular as a primary treatment, recurrent disease will
be less sensitive to chemotherapy.Chemotherapy for adenocarcinoma of the cervixRegarding advanced or recurrent adenocarcinoma of the
cervix, a standard regimen is yet to be established. A majority
of studies have so far focused only on the most common
histological type, that is, squamous cell carcinoma. Cisplatin
achieved four partial responses among 20 patients (20%) [31].
The GOG performed a Phase II study on paclitaxel for
advanced adenocarcinoma of the cervix [32]. A total of 42
assessable patients were initially recruited into the study and
13 responses were seen (four patients had a complete
response, and nine patients had a partial response). The overall
RR was 31%. Kitagawa et al reported that TC therapy ach-
ieved 40% partial response (4/10) but no complete response
[29]. Recently, the incidence of adenocarcinoma has increased
and the recurrence rate of adenocarcinoma is higher than
squamous cell carcinoma. Therefore, a large-scale clinical
study is necessary.Perspective on chemotherapy for advanced or recurrent
cervical cancerThe incidence of cervical cancer is decreasing in devel-
oping countries. However, because chemotherapy has been
introduced as a primary treatment, chemotherapy for recurrent
disease is considered a second-line treatment. In general,second-line treatment could be less effective than first-line,
probably due to drug resistance. Radiation induces fibrosis
around the cancer cells and so concentrations of chemother-
apeutic agents cannot reach the cytocidal level in tumors. To
break such conditions in recurrent cervical cancer, a molecular
targeting agent might be one solution. The GOG recently
conducted a Phase III study of chemotherapy (topotecan and
paclitaxel) with and without bevacizumab [33]. The results
will be presented at the American Society of Clinical
Oncology 2013 Annual Meeting. Along with molecular tar-
geting agents, new strategies are expected to emerge.References
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